Only weeks after filing a patent infringement suit against marketing partner Syncor International, Du Pont Pharmaceuticals this month terminated the litigation. In a joint press release, the two companies announced that their dispute has been resolved.
Only weeks after filing a patent infringement suit against marketing partner Syncor International, Du Pont Pharmaceuticals this month terminated the litigation. In a joint press release, the two companies announced that their dispute has been resolved. The conflict was a misunderstanding, according to Robert Funari, president and CEO of Syncor. The firms declined to provide further details on the matter.
The decision brings a quick end to a tussle that surprised market watchers. On June 17, North Billerica, MA-based Du Pont filed suit against Syncor with the Mexican Institute of Industrial Property, alleging that Syncors subsidiary, Syncor de Mexico, has illegally bought and sold Cardiolite kits, including counterfeit Cardiolite, in Mexico (SCAN 8/4/99). Syncor of Woodland Hills, CA, issued a strong denial of the charges, and filed a defense.
Both companies emphasized the importance of their U.S. relationship in resolving the dispute. The two firms rely heavily on each other: Syncor has been Du Ponts primary U.S. distributor of Cardiolite since the products launch, and distributes more than 80% of the unit doses sold in the U.S.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.